Multicancer blood test moves closer to FDA approval
A blood test designed to detect signals from more than 50 types of cancer before symptoms appear could be on its way to FDA approval, after an advisory panel of experts issued a favourable recommendation.
By a vote of 7-2, with one abstention, the FDA’s Molecular and Clinical Genetics Devices Panel backed the view that the benefits of the Galleri blood test outweigh its risks when used to screen people aged 50 and over.
The same panel voted unanimously that Galleri is safe, and by 6-4 that there is sufficient evidence to support the test’s effectiveness.
BREAKING